Jørgensen, Astrid Sissel
Brandum, Emma Probst
Mikkelsen, Jeppe Malthe
Orfin, Klaudia A.
Boilesen, Ditte Rahbæk
Egerod, Kristoffer Lihme
Moussouras, Natasha A.
Vilhardt, Frederik
Kalinski, Pawel
Basse, Per
Chen, Yen-Hsi
Yang, Zhang
Dwinell, Michael B.
Volkman, Brian F.
Veldkamp, Christopher T.
Holst, Peter Johannes
Lahl, Katharina
Goth, Christoffer Knak
Rosenkilde, Mette Marie
Hjortø, Gertrud Malene http://orcid.org/0000-0002-0057-6371
Funding for this research was provided by:
Novo Nordisk Fonden (0057954)
Lundbeckfonden
Statens Naturvidenskabelige Forskningsrad (DNRF107)
Article History
Received: 4 December 2020
Revised: 4 August 2021
Accepted: 20 August 2021
First Online: 29 September 2021
Declarations
:
: Astrid Sissel Jørgensen, Peter Johannes Holst, Mette Marie Rosenkilde, and Gertrud Malene Hjortø are inventors of a patent regarding the use of peptides based on the sequence of CCL21 C-terminus for use in anti-cancer immunotherapy. Mike Dwinell and Brian F. Volkman have ownership interests in Protein Foundry, LLC and XLock Biosciences, LLC. Emma Probst Brandum, Christoffer Knak Goth, Jeppe Malthe Mikkelsen, Klaudia A. Orfin, Ditte Rahbæk Boilesen, Kristoffer Lihme Egerod, Natasha A. Moussouras, Frederik Vilhardt, Pawel Kalinski, Per Basse, Yen-Hsi Chen, Zhang Yang, and Christopher T. Veldkamp do not have competing interests.
: The local ethics committee at Faculty of Health and Medical Sciences at the University of Copenhagen (Research Ethics Committee for Sund and Science, University of Copenhagen) found the project exempt from approval.
: Written informed consent was obtained from the donors.
: Not applicable.